CHADDS FORD, Pa., Jan. 4, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it will present at the J.P. Morgan 29th Annual Healthcare Conference on Monday, January 10, 2011 at 1:30 p.m. PT. David P. Holveck, president and CEO of Endo, will review the company's products and development programs.
The presentation will be webcast live and can be accessed from Endo's website at www.endo.com under the investors section.
Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit www.endo.com.